- Home
- FINV vs NVCR Comparison
FINV vs NVCR Comparison
Compare FINV & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FINV | NVCR |
|---|---|---|
| Founded | 2007 | 2000 |
| Country | China | Switzerland |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | FINV | NVCR |
|---|---|---|
| Price | $5.26 | $12.74 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $11.55 | ★ $28.42 |
| AVG Volume (30 Days) | 1.8M | ★ 1.9M |
| Earning Date | 11-19-2025 | 10-30-2025 |
| Dividend Yield | ★ 5.50% | N/A |
| EPS Growth | ★ 27.76 | N/A |
| EPS | ★ 1.50 | N/A |
| Revenue | ★ $1,969,555,571.00 | $642,269,000.00 |
| Revenue This Year | $5.54 | $9.75 |
| Revenue Next Year | N/A | $5.62 |
| P/E Ratio | $3.49 | ★ N/A |
| Revenue Growth | 8.81 | ★ 11.17 |
| 52 Week Low | $4.70 | $10.70 |
| 52 Week High | $11.08 | $34.13 |
Technical Indicators
Market Signals| Indicator | FINV | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 47.13 | 53.02 |
| Support Level | $5.05 | $12.30 |
| Resistance Level | $5.30 | $13.94 |
| Average True Range (ATR) | 0.17 | 0.60 |
| MACD | 0.07 | 0.05 |
| Stochastic Oscillator | 60.00 | 61.90 |
Price Performance
Historical ComparisonAbout FINV FinVolution Group
FinVolution Group is a provider of online consumer finance in China. The company offers various loan products, making financial services available to borrowers anytime, anywhere; designs a loan transaction process, and offers tailored risk-based pricing. It offers short-term loans to borrowers to meet immediate credit needs while allowing them to gradually establish their credit history through activities on the company's platform. The company generates revenues from fees charged to borrowers. The Group's long-lived assets are located in the PRC, and its revenues are derived from within the PRC.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.